Treatment Strategies for SREAT: Steroids and Beyond
At a Glance
SREAT is primarily treated with high-dose corticosteroids like intravenous methylprednisolone followed by an oral prednisone taper. For patients who do not respond to steroids or who relapse during tapering, second-line therapies like IVIG, plasmapheresis, or immunosuppressants are often used.
The hallmark of SREAT is right in its name: steroid-responsive. For the majority of patients, the introduction of high-dose corticosteroids brings a rapid and dramatic improvement in neurological and psychiatric symptoms [1][2]. However, treatment is rarely a one-time event; it is often a long-term process of stabilizing the immune system [3].
First-Line Treatment: The Steroid Protocol
The standard “starting line” for SREAT treatment involves calming brain inflammation as quickly as possible [3].
- Initial Pulse: Most patients begin with high-dose intravenous (IV) methylprednisolone (often 1,000 mg per day) for 3 to 5 days [3][4].
- The Taper: After the IV pulses, patients usually transition to oral prednisone. This dose is gradually reduced (tapered) over several months to a year, depending on your symptoms [4][5].
- Caution: Steroids should never be stopped abruptly. Doing so can cause a severe “rebound” of symptoms or a dangerous drop in blood pressure known as an adrenal crisis.
The Reality of Steroid Side Effects
While steroids are life-saving for SREAT, long-term, high-dose use comes with significant side effects. It is critical to be aware of these so you do not mistake medication side effects for a disease relapse. Common side effects include:
- Severe insomnia and jitteriness.
- Extreme mood swings, irritability, or even steroid-induced psychosis.
- Weight gain, particularly around the face and abdomen.
- Long-term risks like increased blood sugar (steroid-induced diabetes) and weakened bones (osteoporosis).
Your primary care doctor can help monitor your blood sugar and prescribe medications to protect your bones while you are on steroids.
Measuring Success: Objective Response
Because steroids can cause a temporary “mood boost” or “steroid buzz,” doctors look for objective signs that the treatment is working specifically on the brain inflammation [3]. This might include:
- Cognitive Testing: Measurable improvement in scores on memory or attention tests [6][3].
- Physical Exam: A clear resolution of tremors, “stroke-like” weakness, or balance issues [2][7].
- EEG Normalization: If your initial brain wave test showed “slowing,” a repeat test should show normal rhythms [8][3].
When Steroids Aren’t Enough
Some patients are steroid-refractory (don’t improve on steroids) or steroid-dependent (symptoms return every time the dose is lowered) [9][10]. In these cases, second-line treatments may be used:
- IVIG (Intravenous Immunoglobulin): A treatment that uses antibodies from healthy donors to “reset” your immune system [11][1].
- Plasmapheresis (PLEX): Also called “plasma exchange,” this process filters your blood to remove harmful antibodies and inflammatory proteins [9][10].
Preventing Relapse: Maintenance Therapy
Relapses are common in SREAT; research indicates approximately 55% of patients experience a return of symptoms during the steroid taper [3]. To prevent this and avoid the long-term toxicity of steroids, doctors may prescribe steroid-sparing agents [12].
These are powerful immunosuppressants that dampen your immune system over the long term to prevent it from attacking the brain again. Common options include:
These medications can leave you more susceptible to infections, so close monitoring is required. Maintenance therapies may be continued for an average of two years to ensure the brain remains protected [3]. Successful management requires a close partnership between you, your neurologist, and often a rheumatologist or immunologist.
Common questions in this guide
What is the first-line treatment for SREAT?
How do doctors know if SREAT treatment is working?
What happens if SREAT symptoms do not improve with steroids?
Why might I need a steroid-sparing medication for SREAT?
What are the side effects of high-dose steroids used for SREAT?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What objective tests (like a repeat EEG or cognitive screening) will you use to measure my response to the steroids?
- 2.What is the planned timeline for my steroid taper, and what signs of relapse should I look for?
- 3.How will we manage the side effects of high-dose steroids, such as insomnia, mood changes, or impacts on bone health and blood sugar?
- 4.If my symptoms don't improve significantly after the first round of steroids, when do we consider treatments like IVIG or plasmapheresis?
- 5.If I have a relapse while tapering, what 'steroid-sparing' medication would you recommend for me?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (12)
- 1
Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis Masquerading Sepsis.
Estaris J, Bansil S, Nishimura Y
Cureus 2023; (15(5)):e38826 doi:10.7759/cureus.38826.
PMID: 37303426 - 2
Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis Presenting With Parkinsonism.
Hicham G, Naji Y, Hrouch W, et al.
Cureus 2024; (16(3)):e56184 doi:10.7759/cureus.56184.
PMID: 38618344 - 3
Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis.
Valencia-Sanchez C, Pittock SJ, Mead-Harvey C, et al.
Brain communications 2021; (3(2)):fcaa233 doi:10.1093/braincomms/fcaa233.
PMID: 34061124 - 4
A Challenging Diagnosis of Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis (SREAT) in a Systemic Lupus Erythematosus (SLE) Patient With Hashimoto Encephalopathy (HE): A Case Report.
Genidy R, Abbas A, Adi AAK, et al.
Cureus 2024; (16(11)):e73262 doi:10.7759/cureus.73262.
PMID: 39655145 - 5
Psychiatric Presentations Heralding Hashimoto's Encephalopathy: A Systematic Review and Analysis of Cases Reported in Literature.
Menon V, Subramanian K, Thamizh JS
Journal of neurosciences in rural practice 2017; (8(2)):261-267 doi:10.4103/jnrp.jnrp_440_16.
PMID: 28479803 - 6
A novel assessment and treatment approach to patients with Hashimoto's encephalopathy.
Laycock K, Chaudhuri A, Fuller C, et al.
Endocrinology, diabetes & metabolism case reports 2018; (2018()) doi:10.1530/EDM-17-0117.
PMID: 29732162 - 7
Sudden-onset Encephalopathy: Do not ignore the Possibility of Hashimoto's Encephalopathy.
Shariff EM
Neurology India 2020; (68(3)):681-683 doi:10.4103/0028-3886.289015.
PMID: 32643688 - 8
SREAT presenting as decades of intractable seizures and isolated delusional episodes with clinical, laboratory, and EEG confirmation of treatment response.
Tjong E, Gardner R, Peng YY
SAGE open medical case reports 2019; (7()):2050313X19850051 doi:10.1177/2050313X19850051.
PMID: 31205712 - 9
Two PerPLEXing Cases of Hashimoto's Encephalopathy Unresponsive to Steroid and Intravenous Immunoglobulin Therapy.
Karan A, Nuthulaganti SR, Zhang Y, et al.
Cureus 2022; (14(7)):e26853 doi:10.7759/cureus.26853.
PMID: 35974865 - 10
Steroid-responsive encephalopathy associated with autoimmune thyroiditis presenting as cortisone sensible psychosis with reversible leukoencephalopathy.
Runge K, Rauer S, Waibel E, et al.
Journal of neuroimmunology 2023; (382()):578177 doi:10.1016/j.jneuroim.2023.578177.
PMID: 37579547 - 11
The use of intravenous immunoglobulin in the treatment of Hashimoto's encephalopathy: case based review.
Şorodoc V, Constantin M, Asaftei A, et al.
Frontiers in neurology 2023; (14()):1243787 doi:10.3389/fneur.2023.1243787.
PMID: 37745658 - 12
[Sarcoidosis : Renal manifestations].
Löffler C, Bergner R
Zeitschrift fur Rheumatologie 2017; (76(5)):398-407 doi:10.1007/s00393-017-0301-9.
PMID: 28405755
This page provides educational information about SREAT treatment protocols. Always consult your neurologist or care team before adjusting steroid doses or starting new therapies.
Get notified when new evidence is published on Steroid-responsive encephalopathy associated with autoimmune thyroiditis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.